Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10513636rdf:typepubmed:Citationlld:pubmed
pubmed-article:10513636lifeskim:mentionsumls-concept:C0013216lld:lifeskim
pubmed-article:10513636lifeskim:mentionsumls-concept:C0020205lld:lifeskim
pubmed-article:10513636lifeskim:mentionsumls-concept:C1334691lld:lifeskim
pubmed-article:10513636lifeskim:mentionsumls-concept:C0023828lld:lifeskim
pubmed-article:10513636pubmed:issue9lld:pubmed
pubmed-article:10513636pubmed:dateCreated1999-11-24lld:pubmed
pubmed-article:10513636pubmed:abstractTextThe inhibitory effects of the hybrid liposomes on the growth of B-16 melanoma cells in vitro and in vivo were examined. The 50% inhibitory concentration of the hybrid liposomes composed of 90 mol% dimyristoylphosphatidylcholine (DMPC) and 10 mol% polyoxyethylenedodecyl ether (C12(EO)10) was one-twelfth of that of DMPC liposomes. It was noteworthy that for the first time significantly prolonged survival was obtained using a mouce model of carcinoma after the administration of the hybrid liposomes of 90 mol% DMPC/10 mol% C12(EO)n (n=10 or 23) without antitumor drugs.lld:pubmed
pubmed-article:10513636pubmed:languageenglld:pubmed
pubmed-article:10513636pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10513636pubmed:citationSubsetIMlld:pubmed
pubmed-article:10513636pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10513636pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10513636pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10513636pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10513636pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10513636pubmed:statusMEDLINElld:pubmed
pubmed-article:10513636pubmed:monthSeplld:pubmed
pubmed-article:10513636pubmed:issn0918-6158lld:pubmed
pubmed-article:10513636pubmed:authorpubmed-author:MatsumotoYYlld:pubmed
pubmed-article:10513636pubmed:authorpubmed-author:MiyagiMMlld:pubmed
pubmed-article:10513636pubmed:authorpubmed-author:TsuzakiKKlld:pubmed
pubmed-article:10513636pubmed:authorpubmed-author:KanneWWlld:pubmed
pubmed-article:10513636pubmed:authorpubmed-author:UeokaRRlld:pubmed
pubmed-article:10513636pubmed:issnTypePrintlld:pubmed
pubmed-article:10513636pubmed:volume22lld:pubmed
pubmed-article:10513636pubmed:ownerNLMlld:pubmed
pubmed-article:10513636pubmed:authorsCompleteYlld:pubmed
pubmed-article:10513636pubmed:pagination1013-4lld:pubmed
pubmed-article:10513636pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10513636pubmed:meshHeadingpubmed-meshheading:10513636...lld:pubmed
pubmed-article:10513636pubmed:meshHeadingpubmed-meshheading:10513636...lld:pubmed
pubmed-article:10513636pubmed:meshHeadingpubmed-meshheading:10513636...lld:pubmed
pubmed-article:10513636pubmed:meshHeadingpubmed-meshheading:10513636...lld:pubmed
pubmed-article:10513636pubmed:meshHeadingpubmed-meshheading:10513636...lld:pubmed
pubmed-article:10513636pubmed:meshHeadingpubmed-meshheading:10513636...lld:pubmed
pubmed-article:10513636pubmed:meshHeadingpubmed-meshheading:10513636...lld:pubmed
pubmed-article:10513636pubmed:meshHeadingpubmed-meshheading:10513636...lld:pubmed
pubmed-article:10513636pubmed:meshHeadingpubmed-meshheading:10513636...lld:pubmed
pubmed-article:10513636pubmed:meshHeadingpubmed-meshheading:10513636...lld:pubmed
pubmed-article:10513636pubmed:meshHeadingpubmed-meshheading:10513636...lld:pubmed
pubmed-article:10513636pubmed:year1999lld:pubmed
pubmed-article:10513636pubmed:articleTitleChemotherapy with hybrid liposomes for melanomatosis.lld:pubmed
pubmed-article:10513636pubmed:affiliationGraduate Course of Applied Chemistry, Kumamoto Institute of Technology, Japan.lld:pubmed
pubmed-article:10513636pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10513636pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed